10 August 2020
Visiongain has launched a new report Pharmaceutical Contract Manufacturing Market Report 2020-2030: Forecasts by Product Category (Pharmaceutical Product Manufacturing, Biological Product Manufacturing), by Drug Type (API Manufacturing, FDF Manufacturing), by API (Small Molecule, Large Molecule, High Potency API (HPAPI)), by FDF (Solid Dose Formulation, Liquid Dose Formulation, Injectable Dose Formulation, Other FDFs), by End-user (Big Pharma, Small & Mid-size Pharma, Generic Pharmaceutical Companies, Other End-users). PLUS Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Pharmaceutical Contract Manufacturing market was valued at US$ xx billion in 2019 and is projected to reach at a market value of US$ xx billion by 2030. Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry. It is a well-known fact that future of the pharmaceutical/biopharmaceutical industry depends on innovation, and innovation comes from collaborations or partnerships. Contract manufacturers that perform custom synthesis and produce intermediates, active pharmaceutical ingredients and dosage forms are becoming increasingly important for the drug developers to conduct their business more efficiently. Rapid economic growth in the emerging markets is also advancing the pharmaceutical/biopharmaceutical contract manufacturing market. Cost, once considered the only reason for outsourcing, is now accomplished by quality and reliability.
COVID-19 Impact on Pharmaceutical Contract Manufacturing Market
Due to the recent outbreak of COVID-19, the changing delivery chain scenario is likely to have a prominent effect in the short term on global contract manufacturing, including China. That said, it will help stakeholders absorb this impact by taking steps by pharmaceutical players and contract producers. The demand for large-scale contract manufacturing is expected to increase significantly as pharmaceutical companies start full-scale operations following the coronavirus outbreak. After the end of the COVID-19 pandemic, several organizations will seek to increase their productivity to meet the growing demand. This means that such larger companies should appoint contract development and manufacturing organizations to deal with losses suffered during the crisis. In addition, numerous governmental bodies develop innovative plans to boost contract development and producing organizations to boost productivity for other bigger organizations.
Growing Demand And Acceptability Of Biosimilars Can Be Seen As A Big Opportunity For Contract Manufacturing
Growing demand and acceptability of biosimilars can be seen as a big opportunity for contract manufacturing and research organizations. The requirement of affordable healthcare and upcoming patent expiries of innovative biologic drugs offers significant opportunities for biosimilars. Large pharma and biopharma companies see a huge opportunity in biosimilars. Rather than jump into the market on their own, most are interested in sharing their risks and working with collaborators. They are forming joint ventures or partnerships with the outsourcing providers.
Bio/Pharmaceutical Manufacturers’ Move Toward Strategic Collaboration With Drug Delivery Technology Companies
Rising healthcare costs, patent cliffs, the highly competitive pharmaceutical market and the need to develop innovative therapies are pushing researchers and market players to search for alternative and new drug delivery technologies. The resulting advanced drug delivery industry is playing a major role in shaping the bio/pharmaceutical industry. Companies with proprietary drug delivery technologies are collaborating with drug manufacturers to apply their technologies to existing products to protect themselves from generic versions and to further develop new drugs. Both the licensing and strategic collaborative business models exist in the drug delivery industry.
Lack of Manufacturing and Packaging Capabilities
Numerous small drug developing companies do not have their own manufacturing facilities and packaging capabilities, so they are dependent upon outsourcing providers for their manufacturing and packaging needs. Halozyme engaged third parties to manufacture bulk rHuPH20, PEGPH20 and Hylenex recombinant. The company has supply agreement
Some of the companies profiled in the report include Catalent Inc., Lonza Group AG, Evonik Industries AG, Teva Pharmaceutical Industries Ltd, Mylan NV, AbbVie Inc., Piramal Enterprises Ltd, Consort Medical plc, Baxter International Inc., Alkermes Plc, Bayer AG, GlaxoSmithKline plc, and NIPRO CORPORATION.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
11 October 2021
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
07 October 2021
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
06 October 2021
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market